scholarly journals Serum uric acid level and renal function tests in hypertensive patients treated by captopril

2013 ◽  
Vol 13 (2) ◽  
pp. 1-10
Author(s):  
Dr. Wahda B Al-Youzbaki ◽  
Yasir Y T Al-Taee
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients ◽  
Function Tests ◽  
Renal Function Tests

scholarly journals Serum Uric Acid Level, Longitudinal Blood Pressure, Renal Function, and Long-Term Mortality in Treated Hypertensive Patients

Hypertension ◽  
2013 ◽  
Vol 62 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Jesse Dawson ◽  
Panniyammakal Jeemon ◽  
Lucy Hetherington ◽  
Caitlin Judd ◽  
Claire Hastie ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Hypertensive Patients ◽  
Long Term Mortality

U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2

2020 ◽  
Vol 44 (1) ◽  
pp. 107-116 ◽  
Author(s):  
Kazuma Mori ◽  
Masato Furuhashi ◽  
Marenao Tanaka ◽  
Keita Numata ◽  
Takashi Hisasue ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Female Subjects

scholarly journals Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction

2021 ◽  
Author(s):  
Toshinari Takahashi ◽  
Takanobu Beppu ◽  
Yuji Hidaka ◽  
Tatsuo Hosoya
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Renal Dysfunction ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Patient Groups ◽  
Urate Reabsorption

Abstract Background Dotinurad is a selective urate reabsorption inhibitor (SURI), which selectively inhibits URAT1 to lower serum uric acid levels in patients with hyperuricemia. Herein, the effects of dotinurad were compared among patient groups with different stages of renal dysfunction. Methods Patient data from four clinical trials were pooled and divided into four groups according to the stage of renal dysfunction to compare the effects of dotinurad at different stages. The grouping (stages G1–G3b) was based on the estimated glomerular filtration rate (eGFR) of the patients. In addition, patient data from a long-term study (34 or 58 weeks) were evaluated in the same manner. Results In the pooled analysis, the percentage of patients achieving a serum uric acid level of ≤ 6.0 mg/dL was 64.7–100.0% at a dose of 2 or 4 mg. In the long-term analysis, the percentage of patients achieving a serum uric acid level of ≤ 6.0 mg/dL was 60.0–100.0% at a dose of 2 or 4 mg. Although the outcomes in stage G3b were worse due to higher baseline serum uric acid levels, satisfactory outcomes were observed in all stages. Even in stages G3a and G3b, when renal function declined, the eGFR remained constant throughout the dose period. Conclusion The efficacy of dotinurad was confirmed in hyperuricemic patients with normal renal function (stage G1) and mild to moderate renal dysfunction (stage G2–G3b). Dotinurad was found to be effective in the treatment of hyperuricemia in patients with mild to moderate renal dysfunction.

Sign in / Sign up

Export Citation Format

Share Document